Market Currents
Johnson & Johnson (JNJ) says the FDA has approved an 800mg tablet for Prezista, an HIV...
-
Friday, November 9, 2012, 5:16 PM ETJohnson & Johnson (JNJ) says the FDA has approved an 800mg tablet for Prezista, an HIV treatment for patients with no darunavir resistance-associated mutations. The drug is taken with ritonavir and in combination with other HIV medicines. Prezista is co-developed with Janssen Therapeutics, a division of JNJ owned Janssen Pharmaceutical.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
